Lorus Therapeutics Financials - The Globe and Mail

Quarter Quarter end
Sales
Cost of sales
Gross margin
Operating expenses:
Research and development
Selling, general and administrative
Total operating expenses
Operating income or loss
Interest expense
Depreciation and amortization
Other income and expenses:
Foreign exchange
Unusual expenses
Gain or loss on sale of assets
Minority interest
Equity in affiliates
Other
Total other items
Earnings before income taxes
Provision for income taxes
Discontinued operations
Extraordinary items
Earnings
Beginning retained earnings
Common dividends
Preferred dividends
Other
Retained earnings
Average number of shares:
Basic
Diluted
EPS:
Basic
Diluted
Dividend per share

Q1/13 Aug 31, 2012	Q2/12 Nov 30, 2011	Q1/12 Aug 31, 2011	Q4/11 May 31, 2011
0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00


0.65	0.65	0.58	0.45
0.60	0.80	0.53	0.58
1.25	1.45	1.11	1.03


-1.25	-1.45	-1.11	-1.03

0.01	0.00	0.00	0.00
0.01	0.01	0.01	0.02

0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00
0.01	0.00	0.00	0.00
0.01	0.00	0.00	0.00


-1.26	-1.46	-1.12	-1.04

0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00


-1.26	-1.46	-1.12	-1.04

-194.39	-190.90	0.00	-188.08
0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00
0.00	-0.00	0.00	0.00
-195.66	-192.36	-190.90	-189.12


42.25	21.17	17.51	15.68
--	--	--	--


-0.03	-0.07	-0.06	-0.06
-0.03	-0.07	-0.06	-0.06

0.00	0.00	0.00	0.00

The Globe and Mail